# BPC-157 TB-500: The Wolverine Research Blend, Read Off the Studies > BPC-157 TB-500 pairs two synthetic peptides — a cytoprotective leg and a cell-migration leg. This terminal posts the confirmed constituent findings, the missing combination data, and the regulatory status, every datum cited. Two constituent positions, read off the published record: BPC-157 the cytoprotective leg, TB-500 the cell-migration leg. The combination row stays open — no controlled trial has ever closed it. ## What is the Wolverine peptide blend? BPC-157 TB-500 is the research-community name for a two-peptide pairing marketed as "Wolverine." It is not one molecule. It is two synthetic peptides posted side by side: BPC-157, a 15-amino-acid pentadecapeptide (sequence `GEPPPGKPADDAGLV`, ~1419.5 Da) derived from a protein found in human gastric juice [1]; and TB-500, an N-acetylated heptapeptide (`Ac-LKKTETQ`, ~889.0 Da) that corresponds to residues 17-23 of the 43-residue protein Thymosin Beta-4 [7]. The blend has no single molecular weight, CAS number, or structure. Commercial vials are commonly labelled with a combined per-vial mass — for example `10 mg + 10 mg` — but no standardized composition or ratio is clinically validated. Treat the blend as two distinct positions, each carrying its own literature, not as a single characterized drug. The two peptides are described as acting through complementary, largely non-overlapping mechanisms, which is the basis of the "synergy" claim. That synergy is a theoretical extrapolation from each peptide's separate mechanism — the full [combination rationale](/research) is laid out on the research page. No controlled head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together. This terminal posts both halves of that story: the confirmed constituent findings, and the open combination row. ## BPC-157 and TB-500: two positions, two mechanisms Read as positions, BPC-157 and TB-500 occupy different mechanistic lanes. BPC-157 supplies a local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and promotes its internalization, driving the VEGFR2-Akt-eNOS pathway and modulating the nitric-oxide system [2]. In a fully transected rat Achilles tendon, BPC-157 at `10 microg/kg` improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in vitro it reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1]. TB-500 supplies a cytoskeletal, cell-migration signal. Its `LKKTETQ` motif binds monomeric (G-) actin 1:1; X-ray crystallography of a gelsolin-domain-1-Thymosin-Beta-4-actin complex at 2 angstrom resolution established that Thymosin Beta-4 sequesters the actin monomer by capping both ends, preventing polymerization [3]. That actin buffering regulates the cytoskeletal dynamics underlying cell migration and re-epithelialization. One caveat doubles inside the blend. "TB-500" as sold is the `Ac-LKKTETQ` 7-mer, but most efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da), not the fragment [4]. The blend's TB-500 leg leans on parent-protein data. The [difference between BPC-157 and TB-500](/research) is explored in full on the research page. ## BPC 157 TB 500: what the blend is studied for The BPC 157 TB 500 pairing is discussed almost entirely in the context of tissue repair — tendon, ligament, muscle, and wound healing. The rationale is two-mechanism: BPC-157's angiogenic and cytoprotective signal alongside TB-500's actin-regulated cell-migration signal [1][3]. A 2012 review consolidated the Thymosin Beta-4 side of that case — actin binding, cell migration, reduced myofibroblast number, anti-inflammatory and pro-angiogenic activity [4]. What the blend is *not* is a proven combination therapy. A 2025 HSS Journal systematic review of BPC-157 covered 36 studies, only one of them human, and found "no clinical safety data"; it made no mention of TB-500 or combination use [8]. Across the constituent literature the strong signals are preclinical and single-compound. The combination's human efficacy and safety are unproven. This site reads each constituent against its own [research dosing context](/dosage) and posts the regulatory picture on the [Wolverine legal status](/legal-status) page. For the human dataset specifically, see the [BPC-157 TB-500 clinical evidence](/clinical-evidence) terminal. ## What is BPC-157 and TB-500? BPC-157 is Body Protection Compound 157, a synthetic stable fragment of a human gastric-juice protein; it carries the cytoprotective and angiogenic role in the blend [1][2]. TB-500 is a synthetic fragment (`Ac-LKKTETQ`) of Thymosin Beta-4, the body's principal G-actin-sequestering peptide; it carries the cytoskeletal cell-migration role [3][7]. Neither circulates in the body under these names. BPC-157 is a designed stable peptide, and TB-500 is a chemically synthesized 7-mer characterized for doping-control reference [7]. Neither is an approved drug anywhere, and both are prohibited in sport. The full glossary, mechanism breakdown, and the open questions are laid out across this site's [frequently asked questions](/faq) and research pages. ## What is the BPC-157 and TB-500 blend used for in research? In research, the BPC-157 and TB-500 constituents are studied for tissue repair: BPC-157 in tendon-transection, gastrointestinal, and ischemia models [1][2], and Thymosin Beta-4 (the parent of TB-500) in wound-healing, cardiac, and migration models [4]. The blend itself has no validated research protocol — there is no peer-reviewed combination study defining a dose, ratio, or endpoint. Human exposure data exist only for the individual constituents, and are thin: three small BPC-157 pilot studies, and human safety data for full-length Thymosin Beta-4 (not the TB-500 fragment) from two Phase 1 trials [5][6]. The combination remains a research-community construct, not a characterized therapeutic. That distinction is the spine of [the Wolverine blend](/) as documented here. --- A two-position evidence board for the BPC-157 TB-500 blend — each constituent finding posted up where the studies confirm it and down where the combination row stays empty, the FDA 503A and WADA status read off first, and nothing here listed, priced, or for sale.